Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 30;55(10):660.
doi: 10.3390/medicina55100660.

Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion

Giuseppe Coppola  1 , Girolamo Manno  2 , Antonino Mignano  3 , Mirko Luparelli  4 , Antonino Zarcone  5 , Giuseppina Novo  6 , Egle Corrado  7
Affiliations
Review

Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion

Giuseppe Coppola et al. Medicina (Kaunas). .

Abstract

Atrial fibrillation the most common cardiac arrhythmia. Its incidence rises steadily with each decade, becoming a real "epidemic phenomenon". Cardioversion is defined as a rhythm control strategy which, if successful, restores normal sinus rhythm. This, whether obtained with synchronized shock or with drugs, involves a periprocedural risk of stroke and systemic embolism which is reduced by adequate anticoagulant therapy in the weeks before or by the exclusion of left atrial thrombi. Direct oral anticoagulants are safe, manageable, and provide rapid onset of oral anticoagulation; they are an important alternative to heparin/warfarin from all points of view, with a considerable reduction in bleedings and increase in the safety and quality of life of patients.

Keywords: atrial fibrillation (AF); direct oral anticoagulants (DOACs); electrical cardioversion (EC).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Suggested flow chart for atrial fibrillation (AF) cardioversion on the basis of the current European Society of Cardiology (ESC) Guidelines. Transesophageal echocardiogram (TEE), anticoagulant therapy (OAT), left atrial appendage (LAA), sinus rhythm (SR).
Figure 2
Figure 2
Summary of X-VeRT, ENSURE-AF, and EMANATE trials results.
See this image and copyright information in PMC

References

    1. Steffel J., Verhamme P., Potpara T.S., Albaladejo P., Antz M., Desteghe L., Georg Haeusler K., Oldgren J., Reinecke H., Roldan-Schilling V., et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association. Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur. Heart J. 2018;39:1330–1393. doi: 10.1093/eurheartj/ehy136. - DOI - PubMed
    1. Rietbrock S., Heeley E., Plumb J., van Sta T. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am. Heart J. 2008;156:57–64. doi: 10.1016/j.ahj.2008.03.010. - DOI - PubMed
    1. Kulbertus H., Lancellotti P. Fibrillation, an epidemic in the elderly? Rev. Med. Liege. 2014;69:301–308. - PubMed
    1. Puccio D., Novo G., Baiamonte V., Nuccio A., Fazio G., Corrado E., Coppola G., Muratori I., Vernuccio L., Novo S. Atrial fibrillation and mild cognitive impairment: What correlation? Minerva Cardioangiol. 2009;57:143–150. - PubMed
    1. Manno G., Novo G., Corrado E., Coppola G., Novo S. Use of direct oral anticoagulants in very elderly patients: A case report of apixaban in an ultracentenary patient. J. Cardiovasc. Med. (Hagerstown) 2019;20:403–405. doi: 10.2459/JCM.0000000000000752. - DOI - PubMed

MeSH terms